Table 2.
Correlation between GRB2 expression level and clinicopathologic features in ESCC patients (Kendall’s tau-b test)
| Clinical parameters | GRB2 | * P value | |
|---|---|---|---|
|
| |||
| Low-expression | Overexpression | ||
| Age (year) | |||
| < 57.6 | 33 (40.7%) | 48 (59.3%) | 0.779 |
| > 57.6 | 39 (42.9%) | 52 (57.1%) | |
| Gender | |||
| Female | 20 (47.6%) | 22 (52.4%) | 0.389 |
| Male | 52 (40.0%) | 78 (60.0%) | |
| Differentiation grade | |||
| Well | 22 (44.9%) | 27 (55.1%) | 0.931 |
| Moderately | 41 (39.0%) | 64 (61.0%) | |
| Poorly | 9 (50.0%) | 9 (50.0%) | |
| Invasive depth | |||
| Tis, T1, T2 | 3 (30.0%) | 7 (70.0%) | 0.415 |
| T3, T4 | 69 (42.6%) | 93 (57.4%) | |
| Lymph node metastasis | |||
| N0 | 45 (48.9%) | 47 (51.1%) | 0.041 |
| N1, N2, N3 | 27 (33.8%) | 53 (66.2%) | |
| TNM classification | |||
| I, IIa | 45 (48.9%) | 47 (51.1%) | 0.041 |
| IIb, III, IV | 27 (33.8%) | 53 (66.2%) | |
*
P value, significance level is 0.05.